Please wait



(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001193125-21-111505 0001848319 XXXXXXXX LIVE 2 Common Stock, $0.0001 par value per share 03/09/2026 false 0001807120 25056L103 Design Therapeutics, Inc. 6005 Hidden Valley Road Suite 110 Carlsbad CA 92011 Sasha Keough (410) 800-7503 c/o SR One Capital Management, LP 929 Main Street, Suite 200 Redwood City CA 94063 0001848319 N SR One Capital Fund I Aggregator, LP WC N DE 0.00 6526476.00 0.00 6526476.00 6526476.00 N 10.6 PN Y SR One Capital Partners I, LP OO N DE 0.00 6526476.00 0.00 6526476.00 6526476.00 N 10.6 PN Y SR One Capital Management, LLC OO N DE 0.00 6526476.00 0.00 6526476.00 6526476.00 N 10.6 HC Y Simeon George OO N X1 81416.00 6526476.00 81416.00 6526476.00 6607892.00 N 10.7 IN Common Stock, $0.0001 par value per share Design Therapeutics, Inc. 6005 Hidden Valley Road Suite 110 Carlsbad CA 92011 This Amendment No. 2 ("Amendment No. 2") to Schedule 13D amends and supplements the statement on Schedule 13D originally filed on April 9, 2021 (the "Schedule 13D") and Amendment No. 1 thereto filed on December 22, 2022 ("Amendment No. 1") relating to the Common Stock of the Issuer. Certain terms used but not defined in this Amendment No. 2 have the meanings assigned thereto in the Schedule 13D (and Amendment No. 1 thereto). Except as specifically provided herein, this Amendment No. 2 does not modify any of the information previously reported on the Schedule 13D (and Amendment No. 1 thereto). This Amendment No. 2 is being filed to report that the beneficial ownership of Common Stock by the Reporting Persons (as defined below) has decreased by more than 1% as a result of an increase in the number of Common Stock outstanding. SR One Capital Fund I Aggregator, LP ("Aggregator"); SR One Capital Partners I, LP ("Partners I"); SR One Capital Management, LLC ("Parent"); and Simeon George, M.D. ("Dr. George"). Aggregator is directly controlled by its general partner, Partners I. Partners I is directly controlled by its general partner, Parent, and Dr. George controls Parent. Accordingly, each of Partners I, Parent and Dr. George may be deemed to have voting and dispositive power with respect to the Shares owned by Aggregator. The persons named in this Item 2 are referred to individually herein as a "Reporting Person" and collectively as the "Reporting Persons." The address of each Reporting Person for purposes of this filing is c/o SR One Capital Management, LP, 929 Main Street, Suite 200, Redwood City, CA 94063. The principal business of Aggregator is to invest in and assist growth-oriented businesses. The principal business of Partners I is to act as the sole general partner of Aggregator. The principal business of Parent is to act as the sole general partner of Partners I and a number of affiliated partnerships with similar businesses. The principal business of Dr. George is to manage Parent. During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting activities subject to, federal or state securities laws or finding any violation with respect to such laws. During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting activities subject to, federal or state securities laws or finding any violation with respect to such laws. Aggregator and Partners I are limited partnerships organized under the laws of the State of Delaware. Parent is a limited liability company organized under the laws of the State of Delaware. Dr. George is a United States citizen. Not applicable. Not applicable. The percentage of outstanding shares of Common Stock which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage was calculated based on 61,672,279 shares of Common Stock reported by the Issuer to be outstanding as of March 2, 2026, on the Issuer's Form 10-K filed with the Securities Exchange Commission on March 9, 2026. Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets (ii) shared power to vote or to direct the vote: See line 8 of cover sheets (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets. None of the Reporting Persons has effected any transaction in shares of Common Stock during the last 60 days. No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, Common Stock beneficially owned by any of the Reporting Persons. Not applicable. Not applicable. Exhibit 1 - Agreement regarding filing of joint Schedule 13D. Exhibit 2 - Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended. SR One Capital Fund I Aggregator, LP /s/ Sasha Keough Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member 03/11/2026 SR One Capital Partners I, LP /s/ Sasha Keough Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member 03/11/2026 SR One Capital Management, LLC /s/ Sasha Keough Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member 03/11/2026 Simeon George /s/ Sasha Keough Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member 03/11/2026 This Amendment No. 2 to Schedule 13D was executed by Sasha Keough on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.